In National Advertising Division Challenge Admire Aesthetics Voluntarily Discontinues Claims for Compounded Tirzepatide

New York, NY – January 23, 2025 – In a BBB National Programs’ National Advertising Division challenge brought by Eli Lilly and Company, Admire Aesthetics, Inc. voluntarily discontinued certain advertising claims for its compounded tirzepatide product.

The inquiry focused on express and implied claims made by Admire Aesthetics about the benefits, efficacy, and safety of its compounded tirzepatide with B12 product. The challenged claims included statements that patients would experience increased energy levels, enhanced well-being, and superior weight loss effectiveness compared to other products such as Eli Lilly’s Mounjaro.

During the inquiry, Admire Aesthetics informed the National Advertising Division (NAD) that it had permanently discontinued all the challenged claims. NAD will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.

In its advertiser statement, Admire Aesthetics stated that they “fully support the self-regulatory process and remain dedicated to truth in advertising."

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.